Shao-Cheng Lyu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shao-Cheng Lyu has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Qiang He
Division of Hepatobiliary and Pancreaticosplenic Surgery, Department of General Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
12 shared publications- Qiang He
Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital affiliated to Capital Medical University, Beijing, China
9 shared publications - Ren Lang
Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
7 shared publications Jing Wang
Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
5 shared publications- Ren Lang
Division of Hepatobiliary and Pancreaticosplenic Surgery, Department of General Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China
5 shared publications Bing Pan
Division of Hepatobiliary and Pancreaticosplenic Surgery, Department of General Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China
4 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 37550
Correction: The interplay between tumor-intrinsic KRT6A and host-derived immune-nutritional status (PNI) defines prognosis in resectable PDA
- 10 November 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 37550
Open AccessCorrection: The interplay between tumor-intrinsic KRT6A and host-derived immune-nutritional status (PNI) defines prognosis in resectable PDA
- Open Access
- 23 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
The interplay between tumor-intrinsic KRT6A and host-derived immune-nutritional status (PNI) defines prognosis in resectable PDAC
Current anatomic staging inadequately predicts outcomes in resectable pancreatic ductal adenocarcinoma (PDAC). This study integrates tumor-intrinsic KRT6A expression with host-derived prognostic nutritional index (PNI) to develop a novel prognostic model. This retrospective study enrolled 105 patients who underwent pancreaticoduodenectomy for histologically confirmed PDAC between January 2019 and December 2024. KRT6A expression was quantified by immunohistochemistry using computer-assisted image analysis. PNI was calculated as serum albumin (g/L) + 5 × lymphocyte count (10⁹/L). The primary endpoint was disease-free survival (DFS). Univariate and multivariate Cox regression analyses were performed to identify independent prognostic factors. A prognostic nomogram (KSI-Nomo) integrating KRT6A and PNI was constructed and validated using time-dependent ROC curves, calibration plots, and decision curve analysis. Risk stratification was performed based on nomogram total points. KRT6A expression was significantly elevated in poorly differentiated tumors and functionally promoted PDAC cell migration and invasion in vitro. Multivariate analysis identified KRT6A expression (HR = 6.337, 95% CI: 1.733-9.540, P = 0.034) and PNI (HR = 0.953, 95% CI: 0.245-1.702, P = 0.014) as the sole independent prognostic factors for DFS, outperforming conventional inflammatory indices (NLR, PLR, SII) and TNM staging. The KRT6A-PNI nomogram demonstrated excellent discriminative accuracy with AUC values of 0.838 (1-year), 0.836 (2-year), and 0.969 (3-year). Calibration curves showed good agreement between predicted and observed survival probabilities. Decision curve analysis confirmed superior net clinical benefit compared to treat-all or treat-none strategies. Risk stratification identified three distinct prognostic groups: low-risk (30% of patients, 3-year DFS rate 52.3%), intermediate-risk (40%, 38.6%), and high-risk (30%, 12.4%) (log-rank P < 0.001). The KRT6A-PNI model provides superior risk stratification for resectable PDAC, enabling personalized treatment decisions.
- 23 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessThe interplay between tumor-intrinsic KRT6A and host-derived immune-nutritional status (PNI) defines prognosis in resectable PDAC
Current anatomic staging inadequately predicts outcomes in resectable pancreatic ductal adenocarcinoma (PDAC). This study integrates tumor-intrinsic KRT6A expression with host-derived prognostic nutritional index (PNI) to develop a novel prognostic model. This retrospective study enrolled 105 patients who underwent pancreaticoduodenectomy for histologically confirmed PDAC between January 2019 and December 2024. KRT6A expression was quantified by immunohistochemistry using computer-assisted image analysis. PNI was calculated as serum albumin (g/L) + 5 × lymphocyte count (10⁹/L). The primary endpoint was disease-free survival (DFS). Univariate and multivariate Cox regression analyses were performed to identify independent prognostic factors. A prognostic nomogram (KSI-Nomo) integrating KRT6A and PNI was constructed and validated using time-dependent ROC curves, calibration plots, and decision curve analysis. Risk stratification was performed based on nomogram total points. KRT6A expression was significantly elevated in poorly differentiated tumors and functionally promoted PDAC cell migration and invasion in vitro. Multivariate analysis identified KRT6A expression (HR = 6.337, 95% CI: 1.733-9.540, P = 0.034) and PNI (HR = 0.953, 95% CI: 0.245-1.702, P = 0.014) as the sole independent prognostic factors for DFS, outperforming conventional inflammatory indices (NLR, PLR, SII) and TNM staging. The KRT6A-PNI nomogram demonstrated excellent discriminative accuracy with AUC values of 0.838 (1-year), 0.836 (2-year), and 0.969 (3-year). Calibration curves showed good agreement between predicted and observed survival probabilities. Decision curve analysis confirmed superior net clinical benefit compared to treat-all or treat-none strategies. Risk stratification identified three distinct prognostic groups: low-risk (30% of patients, 3-year DFS rate 52.3%), intermediate-risk (40%, 38.6%), and high-risk (30%, 12.4%) (log-rank P < 0.001). The KRT6A-PNI model provides superior risk stratification for resectable PDAC, enabling personalized treatment decisions.
- 11 May 2026
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 25 (4) , 463-468
Conversion therapy with arterial reconstruction: Redefining the resect-ability of locally advanced pancreatic cancer
- 11 May 2026
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 25 (4) , 463-468
Conversion therapy with arterial reconstruction: Redefining the resect-ability of locally advanced pancreatic cancer
- Open Access
Combined Model of Inflammatory-Nutritional Indicators and Tumor Markers for Predicting Prognosis in Patients with Distal Cholangiocarcinoma: A Retrospective Cohort Study
Objectives: The TNM staging system for distal cholangiocarcinoma (dCCA) has limited accuracy due to its anatomical basis. This study developed a prognostic model integrating inflammatory-nutritional markers and tumor biomarkers to improve risk stratification. Methods: We analyzed 208 dCCA patients undergoing pancreaticoduodenectomy (2017–2024). Independent prognostic factors for overall survival (OS) were identified via Cox regression, including tumor marker (corrected CA19-9) and host status markers (PLR, CAR, and PNI). A nomogram was constructed and evaluated using calibration, ROC, and DCA. Patients were risk-stratified using the model’s score. Results: Four independent factors were identified: corrected CA19-9 (HR = 2.438), PLR (HR = 2.041), CAR (HR = 2.477), and PNI (HR = 0.415). The nomogram showed excellent discrimination for 1-, 3-, and 5-year OS (AUC: 0.847, 0.824, 0.858), good calibration, and clinical utility per DCA. Risk stratification significantly distinguished high-risk (n = 110) from low-risk (n = 98) groups (log-rank p < 0.0001). Discussion: This multidimensional model (tumor burden, inflammation, nutrition) outperforms TNM staging, highlighting host systemic status. Despite its single-center retrospective design, it shows promise for personalized risk assessment. Conclusion: The CINS (Cholangiocarcinoma Inflammation–Nutrition Score) accurately predicts prognosis and effectively risk-stratifies dCCA patients, aiding personalized treatment planning.
Open AccessCombined Model of Inflammatory-Nutritional Indicators and Tumor Markers for Predicting Prognosis in Patients with Distal Cholangiocarcinoma: A Retrospective Cohort Study
Objectives: The TNM staging system for distal cholangiocarcinoma (dCCA) has limited accuracy due to its anatomical basis. This study developed a prognostic model integrating inflammatory-nutritional markers and tumor biomarkers to improve risk stratification. Methods: We analyzed 208 dCCA patients undergoing pancreaticoduodenectomy (2017–2024). Independent prognostic factors for overall survival (OS) were identified via Cox regression, including tumor marker (corrected CA19-9) and host status markers (PLR, CAR, and PNI). A nomogram was constructed and evaluated using calibration, ROC, and DCA. Patients were risk-stratified using the model’s score. Results: Four independent factors were identified: corrected CA19-9 (HR = 2.438), PLR (HR = 2.041), CAR (HR = 2.477), and PNI (HR = 0.415). The nomogram showed excellent discrimination for 1-, 3-, and 5-year OS (AUC: 0.847, 0.824, 0.858), good calibration, and clinical utility per DCA. Risk stratification significantly distinguished high-risk (n = 110) from low-risk (n = 98) groups (log-rank p < 0.0001). Discussion: This multidimensional model (tumor burden, inflammation, nutrition) outperforms TNM staging, highlighting host systemic status. Despite its single-center retrospective design, it shows promise for personalized risk assessment. Conclusion: The CINS (Cholangiocarcinoma Inflammation–Nutrition Score) accurately predicts prognosis and effectively risk-stratifies dCCA patients, aiding personalized treatment planning.
- 22 December 2025
- Published by Springer Nature in Surgery Today
- Vol. 56 (7) , 1092-1104
Predictive value of neutrophil-to-platelet ratio for postoperative prognosis in distal cholangiocarcinoma: A retrospective study
Purpose This study aimed to explore the value of neutrophil-to-platelet ratio (NPR) in predicting postoperative prognosis of distal cholangiocarcinoma(dCCA). Methods The optimal cutoff value of NPR was determined using a receiver operator characteristic curve (ROC) analysis. Patients were divided into low- and high-NPR groups, and perioperative data and long-term survival were compared. Independent risk factors for postoperative tumor recurrence and long-term survival were identified using univariate and multivariate analyses. An NPR-based prediction model was established and verified using ROC, calibration curve, and decision curve analyses. Results A total of 168 patients were included. The area under the ROC curve of preoperative NPR was 0.617, and the optimal cutoff value was 0.014. Postoperative disease-free survival and overall survival were significantly longer in the low-NPR group. Univariate and multivariate analyses indicated that NPR > 0.014 was an independent risk factor for postoperative recurrence (RR = 1.745, 95%CI: 1.027–2.965) and long-term survival (RR = 1.837, 95%CI: 1.127–2.993). The NPR-based prediction model could improve the predictive ability for the postoperative prognosis. Patients with a high preoperative NPR may have an advanced TNM stage and portal vein invasion. Conclusion Elevated NPR is an independent risk factor for postoperative tumor recurrence and a poor long-term prognosis in patients with dCCA.
- 22 December 2025
- Published by Springer Nature in Surgery Today
- Vol. 56 (7) , 1092-1104
Predictive value of neutrophil-to-platelet ratio for postoperative prognosis in distal cholangiocarcinoma: A retrospective study
Purpose This study aimed to explore the value of neutrophil-to-platelet ratio (NPR) in predicting postoperative prognosis of distal cholangiocarcinoma(dCCA). Methods The optimal cutoff value of NPR was determined using a receiver operator characteristic curve (ROC) analysis. Patients were divided into low- and high-NPR groups, and perioperative data and long-term survival were compared. Independent risk factors for postoperative tumor recurrence and long-term survival were identified using univariate and multivariate analyses. An NPR-based prediction model was established and verified using ROC, calibration curve, and decision curve analyses. Results A total of 168 patients were included. The area under the ROC curve of preoperative NPR was 0.617, and the optimal cutoff value was 0.014. Postoperative disease-free survival and overall survival were significantly longer in the low-NPR group. Univariate and multivariate analyses indicated that NPR > 0.014 was an independent risk factor for postoperative recurrence (RR = 1.745, 95%CI: 1.027–2.965) and long-term survival (RR = 1.837, 95%CI: 1.127–2.993). The NPR-based prediction model could improve the predictive ability for the postoperative prognosis. Patients with a high preoperative NPR may have an advanced TNM stage and portal vein invasion. Conclusion Elevated NPR is an independent risk factor for postoperative tumor recurrence and a poor long-term prognosis in patients with dCCA.
- Open Access
- 14 November 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 31 (42) , 112354
Development and validation of a predictive model for portal-systemic venous invasion grading in borderline resectable pancreatic cancer
BACKGROUND Portosystemic venous invasion (PSVI) depth critically influences prognosis in borderline resectable pancreatic cancer (BRPC), necessitating precise preoperative discrimination for personalized therapy. AIM To develop and validate a preoperative nomogram integrating computed tomography parameters and carbohydrate antigen 19-9 (CA19-9) kinetics for predicting PSVI depth in treatment-naive BRPC. METHODS This retrospective cohort study analyzed 167 BRPC patients undergoing radical resection between 2011 and 2023. Patients were stratified by pathological PSVI depth [no venous invasion (VI)/adventitial/muscularis propria/intimal]. Kaplan-Meier and ordinal logistic regression identified preoperative predictors from clinical/laboratory/computed tomography parameters (e.g. , circumferential involvement and CA19-9). A nomogram was developed and validated via calibration curves/decision curve analysis. RESULTS PSVI depth significantly stratified survival.: Intimal VI showed worst prognosis (median overall survival: 9 months, 5-year overall survival: 0% vs no VI: 17 months, 12.5%; P < 0.001). Independent predictors: CA19-9 [odds ratio (OR) = 3.819, Wald = 14.125, 95% confidence interval (CI): 1.980-7.410], circumferential involvement (OR = 8.271, Wald = 33.352, 95%CI: 3.950-17.320), and luminal compromise (OR = 3.544, Wald = 8.489, 95%CI: 1.818-6.447). The nomogram achieved C-index = 0.928 (95%CI: 0.889-0.967), with 100-250 points indicating high invasiveness risk. Decision curve analysis confirmed clinical utility (threshold: 0-0.7). CONCLUSION This model integrates routine indicators to preoperatively quantify PSVI depth, guiding precision treatment.
- 14 November 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 31 (42) , 112354
Open AccessDevelopment and validation of a predictive model for portal-systemic venous invasion grading in borderline resectable pancreatic cancer
BACKGROUND Portosystemic venous invasion (PSVI) depth critically influences prognosis in borderline resectable pancreatic cancer (BRPC), necessitating precise preoperative discrimination for personalized therapy. AIM To develop and validate a preoperative nomogram integrating computed tomography parameters and carbohydrate antigen 19-9 (CA19-9) kinetics for predicting PSVI depth in treatment-naive BRPC. METHODS This retrospective cohort study analyzed 167 BRPC patients undergoing radical resection between 2011 and 2023. Patients were stratified by pathological PSVI depth [no venous invasion (VI)/adventitial/muscularis propria/intimal]. Kaplan-Meier and ordinal logistic regression identified preoperative predictors from clinical/laboratory/computed tomography parameters (e.g. , circumferential involvement and CA19-9). A nomogram was developed and validated via calibration curves/decision curve analysis. RESULTS PSVI depth significantly stratified survival.: Intimal VI showed worst prognosis (median overall survival: 9 months, 5-year overall survival: 0% vs no VI: 17 months, 12.5%; P < 0.001). Independent predictors: CA19-9 [odds ratio (OR) = 3.819, Wald = 14.125, 95% confidence interval (CI): 1.980-7.410], circumferential involvement (OR = 8.271, Wald = 33.352, 95%CI: 3.950-17.320), and luminal compromise (OR = 3.544, Wald = 8.489, 95%CI: 1.818-6.447). The nomogram achieved C-index = 0.928 (95%CI: 0.889-0.967), with 100-250 points indicating high invasiveness risk. Decision curve analysis confirmed clinical utility (threshold: 0-0.7). CONCLUSION This model integrates routine indicators to preoperatively quantify PSVI depth, guiding precision treatment.
- Open Access
- 18 September 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 410 (1) , 1
Correction to: Mesenteric approach for borderline resectable pancreatic head cancer: a 13-year retrospective cohort study
- 18 September 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 410 (1) , 1
Open AccessCorrection to: Mesenteric approach for borderline resectable pancreatic head cancer: a 13-year retrospective cohort study
- Open Access
- 29 August 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 410 (1) , 1-10
Mesenteric approach for borderline resectable pancreatic head cancer: a 13-Year retrospective cohort study
Objective To evaluate the value of mesenteric approach for borderline resectable pancreatic head cancer(BRPHC). Methods According to the inclusion and exclusion criteria, the data of 203 patients with borderline resectable pancreatic head cancer(BRPHC) who underwent radical pancreatoduodenectomy in our center from January 2011 to December 2023 were retrospectively analyzed. After detecting the superior mesenteric artery in infracolic compartment to judge that there was vascular invasion but it met the borderline resection criteria, the blood supply was cut off first, then the tissues and organs were resected. And the invaded vessels were resected and reconstructed or replaced, then conventional anastomosis was performed. All patients were divided into mesenteric approach group and conventional approach group according to the operation method. The outcome measures were operation completion, perioperative conditions and overall prognosis. The follow-up time was up to February 2025. Results All 203 patients successfully completed the operation without perioperative death, and confirmed as pancreatic ductal adenocarcinoma by pathological examination. Overall and grouped prognosis: The overall survival rates and disease-free survival rates of 1-, 2-, and 5-year were 51.9%, 25.0%, 8.5% and 28.4%, 12.9%, 3.9% (Fig. 1). The 1-, 2-, and 5-year survival rates of patients in two groups were 62.1%, 40.3%, 21.7% and 44.1%, 14.7%, 1.8% (P = 0.000, X2 = 20.927) (Fig. 2A); The 1-, 2-, and 5-year disease-free survival rates in two groups were 44.9%, 24.5%, 8.2% and 20.8%, 7.5%, 1.9% (P = 0.006, X2 = 7.457) (Fig. 2B). Conclusion The mesenteric approach in infracolic compartment can improve the prognosis of patients with borderline resectable pancreatic head cancer, prolong the postoperative survival time of patients, and reduce the recurrence.
- 29 August 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 410 (1) , 1-10
Open AccessMesenteric approach for borderline resectable pancreatic head cancer: a 13-Year retrospective cohort study
Objective To evaluate the value of mesenteric approach for borderline resectable pancreatic head cancer(BRPHC). Methods According to the inclusion and exclusion criteria, the data of 203 patients with borderline resectable pancreatic head cancer(BRPHC) who underwent radical pancreatoduodenectomy in our center from January 2011 to December 2023 were retrospectively analyzed. After detecting the superior mesenteric artery in infracolic compartment to judge that there was vascular invasion but it met the borderline resection criteria, the blood supply was cut off first, then the tissues and organs were resected. And the invaded vessels were resected and reconstructed or replaced, then conventional anastomosis was performed. All patients were divided into mesenteric approach group and conventional approach group according to the operation method. The outcome measures were operation completion, perioperative conditions and overall prognosis. The follow-up time was up to February 2025. Results All 203 patients successfully completed the operation without perioperative death, and confirmed as pancreatic ductal adenocarcinoma by pathological examination. Overall and grouped prognosis: The overall survival rates and disease-free survival rates of 1-, 2-, and 5-year were 51.9%, 25.0%, 8.5% and 28.4%, 12.9%, 3.9% (Fig. 1). The 1-, 2-, and 5-year survival rates of patients in two groups were 62.1%, 40.3%, 21.7% and 44.1%, 14.7%, 1.8% (P = 0.000, X2 = 20.927) (Fig. 2A); The 1-, 2-, and 5-year disease-free survival rates in two groups were 44.9%, 24.5%, 8.2% and 20.8%, 7.5%, 1.9% (P = 0.006, X2 = 7.457) (Fig. 2B). Conclusion The mesenteric approach in infracolic compartment can improve the prognosis of patients with borderline resectable pancreatic head cancer, prolong the postoperative survival time of patients, and reduce the recurrence.
- Open Access
- 11 August 2025
- Published by Springer Nature in BMC Surgery
- Vol. 25 (1)
Preoperative combined biomarker model of fibrinogen-to-albumin ratio and systemic immune-inflammation index to carbohydrate antigen 19-9 ratio predicts survival in distal cholangiocarcinoma after pancreatoduodenectomy: a retrospective cohort study
To develop a preoperative composite biomarker model integrating FAR and SII/CA19-9 for predicting survival in distal cholangiocarcinoma (DCC) after pancreatoduodenectomy. This retrospective cohort study analyzed 238 DCC patients (2010–2023). Optimal cut-off were determined by ROC analysis (FAR: 8.85, AUC = 0.602; SII/CA19-9: 8, AUC = 0.668). Intergroup comparisons demonstrated no significant differences between the groups. Survival analysis validated pronounced survival disparities across these groups. Multivariable Cox regression identified independent prognostic factors, and a nomogram was constructed for survival prediction. a nomogram integrated independent risk factors into a predictive model, then calibration curves and decision curve analysis (DCA) collectively validated the model’s prognostic capability. The independent Prognostic Factors were FAR > 8.85 (HR = 1.919, 95% CI: 1.333–2.762), SII/CA19-9 ≤ 8 (HR = 0.522, 95% CI: 0.356–0.765), and R1 resection (HR = 0.523, 95% CI: 0.328–0.834). Low SII/CA19-9 (≤ 8) patients had median OS of 17 months vs. 44 months in high-ratio group (P < 0.001). High FAR (> 8.85) correlated with reduced median OS (20 months vs. 51months, P < 0.001). The composite model outperformed AJCC staging (C-index: 0.72 vs. 0.62) and CA19-9 alone (AUC: 0.68 vs. 0.61), with 31% net benefit gain in decision curve analysis. The FAR and SII/CA19-9 composite model enhances preoperative prognostication in DCC, stratifying high-risk patients (low SII/CA19-9 and high FAR) for personalized adjuvant strategies.
- 11 August 2025
- Published by Springer Nature in BMC Surgery
- Vol. 25 (1)
Open AccessPreoperative combined biomarker model of fibrinogen-to-albumin ratio and systemic immune-inflammation index to carbohydrate antigen 19-9 ratio predicts survival in distal cholangiocarcinoma after pancreatoduodenectomy: a retrospective cohort study
To develop a preoperative composite biomarker model integrating FAR and SII/CA19-9 for predicting survival in distal cholangiocarcinoma (DCC) after pancreatoduodenectomy. This retrospective cohort study analyzed 238 DCC patients (2010–2023). Optimal cut-off were determined by ROC analysis (FAR: 8.85, AUC = 0.602; SII/CA19-9: 8, AUC = 0.668). Intergroup comparisons demonstrated no significant differences between the groups. Survival analysis validated pronounced survival disparities across these groups. Multivariable Cox regression identified independent prognostic factors, and a nomogram was constructed for survival prediction. a nomogram integrated independent risk factors into a predictive model, then calibration curves and decision curve analysis (DCA) collectively validated the model’s prognostic capability. The independent Prognostic Factors were FAR > 8.85 (HR = 1.919, 95% CI: 1.333–2.762), SII/CA19-9 ≤ 8 (HR = 0.522, 95% CI: 0.356–0.765), and R1 resection (HR = 0.523, 95% CI: 0.328–0.834). Low SII/CA19-9 (≤ 8) patients had median OS of 17 months vs. 44 months in high-ratio group (P < 0.001). High FAR (> 8.85) correlated with reduced median OS (20 months vs. 51months, P < 0.001). The composite model outperformed AJCC staging (C-index: 0.72 vs. 0.62) and CA19-9 alone (AUC: 0.68 vs. 0.61), with 31% net benefit gain in decision curve analysis. The FAR and SII/CA19-9 composite model enhances preoperative prognostication in DCC, stratifying high-risk patients (low SII/CA19-9 and high FAR) for personalized adjuvant strategies.
- Open Access
- 23 May 2025
- Published by Springer Nature in Research Square
Preoperative fibrinogen/albumin combine SII/CA19-9 to predict prognosis for patients with distal cholangiocarcinoma under pancreatoduodenectomy
Abstract Background: Distal cholangiocarcinoma (DCC) is known as high malignant potential and poor prognosis. FAR can reflect the inflammatory reaction, coagulation function and nutritional status. CA19-9 has been confirmed to be significantly correlated with the diagnosis, recurrence and long-term prognosis of distal cholangiocarcinoma. SII can reflect the local immune response and systemic inflammation. In this study, SII/CA19-9 and FAR were used to predict recurrence and long-term survival of patients with distal cholangiocarcinoma under pancreatoduodenectomy. Methods: According to the inclusion and exclusion criteria, the data of 238 patients with distal cholangiocarcinoma under pancreatoduodenectomy in Department of hepatobiliary surgery, Beijing Chao-Yang Hospital Affiliated to Capital Medical University from January 2010 to December 2024 were retrospectively analyzed. Based on the 1-year survival rates, ROC curve was drawn to determine the optimal cut-off value of SII/CA19-9, and the patients were divided into low ratio group (n=106) and high ratio group (n=132). The risk factors of long-term survival were analyzed, and the survival rate was compared according to SII/CA19-9 ratio. Similarly, based on the 1-year survival rates, ROC curve was drawn to determine the optimal cut-off value of FAR. Then the patients were divided into low FAR group (n=86) and high FAR group (n=152), and the risk factors influencing the long-term survival in different groups were further analyzed separately. Results: The best cut-off value of SII/CA19-9 was 8 (area under curve: 0.670, 95% CI: 0.586-0.754). For the overall patient, SII/CA19-9、invasion of portal vein、lymph node metastasis、chemotherapy cycle were independent risk factors for long-term survival. The overall median survival time of patients with SII/CA19-9 low ratio group and high ratio group was 44 months and 17 months, respectively. The 1-year, 3-year and 5-year overall survival rates were 86.3%, 52.1%, 39.5% and 64.1%, 20.0% and 16.6%, respectively (P = 0.000). For patients with low FAR level, invasion of portal veinand lymph node metastasis were independent risk factors for long-term survival. For patients with high FAR level, SII/CA19-9, invasion of portal vein and chemotherapy cycle were independent risk factors for long-term survival. Conclusion: Compared with CA19-9 alone, SII/CA19-9 is more valuable in judging the long-term survival of distal cholangiocarcinoma, especially with FAR level. The higher preoperative SII/CA19-9 ratio is, the lower FAR is, the better long-term prognosis will be.
- 23 May 2025
- Published by Springer Nature in Research Square
Open AccessPreoperative fibrinogen/albumin combine SII/CA19-9 to predict prognosis for patients with distal cholangiocarcinoma under pancreatoduodenectomy
Abstract Background: Distal cholangiocarcinoma (DCC) is known as high malignant potential and poor prognosis. FAR can reflect the inflammatory reaction, coagulation function and nutritional status. CA19-9 has been confirmed to be significantly correlated with the diagnosis, recurrence and long-term prognosis of distal cholangiocarcinoma. SII can reflect the local immune response and systemic inflammation. In this study, SII/CA19-9 and FAR were used to predict recurrence and long-term survival of patients with distal cholangiocarcinoma under pancreatoduodenectomy. Methods: According to the inclusion and exclusion criteria, the data of 238 patients with distal cholangiocarcinoma under pancreatoduodenectomy in Department of hepatobiliary surgery, Beijing Chao-Yang Hospital Affiliated to Capital Medical University from January 2010 to December 2024 were retrospectively analyzed. Based on the 1-year survival rates, ROC curve was drawn to determine the optimal cut-off value of SII/CA19-9, and the patients were divided into low ratio group (n=106) and high ratio group (n=132). The risk factors of long-term survival were analyzed, and the survival rate was compared according to SII/CA19-9 ratio. Similarly, based on the 1-year survival rates, ROC curve was drawn to determine the optimal cut-off value of FAR. Then the patients were divided into low FAR group (n=86) and high FAR group (n=152), and the risk factors influencing the long-term survival in different groups were further analyzed separately. Results: The best cut-off value of SII/CA19-9 was 8 (area under curve: 0.670, 95% CI: 0.586-0.754). For the overall patient, SII/CA19-9、invasion of portal vein、lymph node metastasis、chemotherapy cycle were independent risk factors for long-term survival. The overall median survival time of patients with SII/CA19-9 low ratio group and high ratio group was 44 months and 17 months, respectively. The 1-year, 3-year and 5-year overall survival rates were 86.3%, 52.1%, 39.5% and 64.1%, 20.0% and 16.6%, respectively (P = 0.000). For patients with low FAR level, invasion of portal veinand lymph node metastasis were independent risk factors for long-term survival. For patients with high FAR level, SII/CA19-9, invasion of portal vein and chemotherapy cycle were independent risk factors for long-term survival. Conclusion: Compared with CA19-9 alone, SII/CA19-9 is more valuable in judging the long-term survival of distal cholangiocarcinoma, especially with FAR level. The higher preoperative SII/CA19-9 ratio is, the lower FAR is, the better long-term prognosis will be.